Peter Voorhees is a Hematology physician affiliated with Levine Cancer Institute. OpenAlex indexes 471 publications with 14,597 citations (h-index 52); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1021 Morehead Medical Dr
Ste A
Charlotte, NC 282042990
Telephone
980-442-2000Registry record last updated 15 Jul 2024.
Clinical trials
- Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Sponsor: Alliance for Clinical Trials in Oncology
- Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Sponsor: Cristina Gasparetto
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Legend Biotech USA Inc.Program year20256 payments
- Janssen Global Services, LLCProgram year20257 payments
- ABBVIE INC.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
30.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor28.9%Acyclovir100%Part D≥62 patientsCorticosteroid1.9%Triamcinolone Acetonide100%Part D<11 patientsMetabolism & gastrointestinal
18.9%Serotonin-3 Receptor Antagonist6.8%Ondansetron Hcl100%Part D≥31 patientsPotassium supplement4.8%Potassium Chloride100%Part D<11 patients+ 3 more classes in this area
Anti-infectives
12.9%Short-acting sulfonamides8.9%Sulfamethoxazole-Trimethoprim100%Part D≥18 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor2.5%Valacyclovir100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2006–2020 per NIH RePORTER. The latest:
- PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
Univ of North Carolina Chapel Hill
FY2020$143,396P30CA016086 - PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
Univ of North Carolina Chapel Hill
FY2019$138,994P30CA016086 - PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
Univ of North Carolina Chapel Hill
FY2018$143,392P30CA016086
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
New England Journal of Medicine
2024 - Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Antoinette Tan, MD
Levine Cancer Institute
Stuart Burri, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”